A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

Exclusion Criteria

• •Other prior or current neurologic or medical disorder which may currently or during the course of the study impair cognition or psychiatric functioning
• •A history of stroke
• •A documented history of transient ischemic attack within the last 12 months
• •History of schizophrenia, schizoaffective or bipolar disorder
• •Currently meets criteria for major depression
• •Within the last 2 years, unstable or clinical significant cardiovascular disease (myocardial infarction, angina pectoris)
• •Inclusion in a research and/or medical protocol involving PET ligands or other radioactive agents within 12 months
• •Present or planned participation in a research and/or medical protocol involving PET ligands or radioactive agents other than study WN25203
• •Have planned or are planning to have exposure to ionizing radiation that in combination with the planned administration with study amyloid PET ligand would result in a cumulative exposure that exceeds local recommended exposure limits